Paraproteinemias Clinical Trials

Active, Not Recruiting

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

NCT06169215

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine, California, United States

UCI Health Laguna Hills Laguna Hills, California, United States

UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States

University of California Davis Comprehensive Cancer Center Sacramento, California, United States

View all 27 locations

View Trial Details

Active, Not Recruiting

Lenalidomide Maintenance in Plasma Cell Myeloma

NCT02538198

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations: Memorial Sloan Kettering Cancer Center Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Bergen Montvale, New Jersey, United States

Memorial Sloan Kettering Cancer Center @ Suffolk Commack, New York, United States

Memorial Sloan Kettering Westchester Harrison, New York, United States

View Trial Details

Active, Not Recruiting

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

NCT04108195

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: City of Hope National Medical Center Duarte, California, United States

City of Hope Orange County Lennar Foundation Cancer Center Irvine, California, United States

University of California San Francisco San Francisco, California, United States

The Blavatnik Family Chelsea Medical Center at Mount Sinai New York, United States

View all 24 locations

View Trial Details

Active, Not Recruiting

A Study of MCARH109 and MCARH125 in People With Multiple Myeloma

NCT05431608

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations: Memorial Sloan Kettering Basking Ridge (Limited protocol activities) Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Monmouth (Limited protocol activities) Middletown, New Jersey, United States

Memorial Sloan Kettering Bergen (Limited protocol activities) Montvale, New Jersey, United States

Memorial Sloan Kettering Commack (Limited protocol activities) Commack, New York, United States

View Trial Details

Active, Not Recruiting

A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma

NCT04181827

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: University of Alabama at Birmingham Birmingham, Alabama, United States

Mayo Clinic Cancer Center-Scottsdale Phoenix, Arizona, United States

Stanford University Medical Center Stanford, California, United States

Colorado Blood Cancer Institute Denver, Colorado, United States

View all 88 locations

View Trial Details

Active, Not Recruiting

A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma

NCT06604715

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations: Princess Margaret Hospital Toronto, Ontario, Canada

Jewish General Hospital Montreal, Quebec, Canada

Seoul National University Hospital Seoul, South Korea

Asan Medical Center Seoul, South Korea

View all 15 locations

View Trial Details

Active, Not Recruiting

A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

NCT05050097

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: University of Alabama Birmingham Birmingham, Alabama, United States

University of California San Francisco San Francisco, California, United States

Colorado Blood Cancer Institute Denver, Colorado, United States

Emory University Atlanta, Georgia, United States

View all 31 locations

View Trial Details

Active, Not Recruiting

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

NCT04923893

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: UCSF San Francisco, California, United States

Yale Cancer Center New Haven, Connecticut, United States

University of Miami Health System Miami, Florida, United States

AdventHealth Cancer Institute Orlando, Florida, United States

View all 136 locations

View Trial Details

Active, Not Recruiting

A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma

NCT06550895

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: University of Iowa Hospital and Clinics Iowa City, Iowa, United States

Norton Cancer Institute Louisville, Kentucky, United States

Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States

Icahn School of Medicine at Mount Sinai New York, United States

View Trial Details

Active, Not Recruiting

A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma

NCT06577025

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: City of Hope Duarte, California, United States

University of California San Francisco San Francisco, California, United States

University of Iowa Hospital and Clinics Iowa City, Iowa, United States

Memorial Sloan Kettering Cancer Center New York, United States

View all 16 locations

View Trial Details

Paraproteinemias

Paraproteinemias trial results

Related conditions